上海市2009～2013年艾滋病抗病毒治疗情况调查  

Investigation on AIDS Antiviral Therapy from 2009 to 2013 in Shanghai

作　　者：韩丹[1] 潘建玲[1] 储文功[1] 卢洪洲[2] 张丽军[2] 

机构地区：[1]第二军医大学药事管理与临床药学教研室,上海200433 [2]复旦大学上海市公共卫生临床中心

出　　处：《药物流行病学杂志》2015年第7期429-432,共4页Chinese Journal of Pharmacoepidemiology

摘　　要：目的:了解上海地区艾滋病患者抗病毒治疗情况,为进一步开展规范化抗病毒治疗提供科学依据。方法:调查上海市公共卫生临床中心的872例接受免费抗病毒治疗的患者,对其资料进行分析。结果:872例患者中,死亡52例,79例合并其他慢性感染,651例(74.66%)坚持服药,无漏服现象,治疗方案以齐多夫定+拉米夫定+依非韦伦为主(53.95%),216例更换药物,绝大多数病例T淋巴细胞CD4+计数明显上升,治疗12个月、18个月和24个月后CD4+细胞计数水平高于治疗前。结论:上海市艾滋病抗病毒治疗效果显著,应继续加强督导,提高治疗成功率。Objective： To understand the antiviral therapy situation analysis of HIV/AIDS patients in Shanghai and to provide scientific bias for further development of standardized antiviral therapy. Methods：The date of 872 patients who received free antiviral therapy in Shanghai public health clinical center were Collected and analyzed. Results： In 872 cases,52 cases died and 79 cases were concurrent with other chronic infection while the medication adherence was 74.66%. The main therapeutic schedule was AZT ＋ 3TC ＋ EFV （53.95%） and 216 cases of total cases had changed drugs. In addition, in the vast majority of cases, CD4^＋ T lymphocytes counts increased obviously and there were more counts respectively in the 12 months, 18 months and 24 months after starting the therapy compared with before starting the therapy. Conclusion：Shanghai antiviral therapy effect was remarkable and relative department should continue to strengthen supervision and improve the treatment success.

关 键 词：艾滋病 抗病毒治疗 T淋巴细胞 CD4^+ 

分 类 号：R952.91[医药卫生—药学]